Croda Reports Encouraging 2025 Results and Sets Ambitious Three-Year Financial Framework

Croda’s 2025: underlying progress, chunky exceptionals, and a clearer three-year roadmap

Here’s the short version. Croda grew sales and underlying profit, generated solid cash, trimmed leverage, and nudged the dividend up. The headline statutory profit took a heavy hit from non-cash charges as the group reset parts of Pharma and its supply chain. Management has now pinned its colours to the mast with a three-year financial framework targeting faster growth, fatter margins, and stronger cash conversion.

• Sales up 6.6% at constant currency to £1,699.4m; volumes +9.6%, price/mix -3.0%.
• Adjusted operating profit up 7.9% at constant currency to £295.3m; margin 17.4% (2024: 17.2%).
• IFRS operating profit £110.1m after £185.2m of adjustments, including £107.3m impairments.
• Free cash flow £161.6m; net debt £523.8m; leverage 1.3x.
• Dividend lifted to 111.0p (2024: 110.0p).

Key numbers investors care about

What drove the year: Consumer Care and Life Sciences did the heavy lifting

Consumer Care: steady growth and standout F&F

• Sales £972.7m, up 7.9% at constant currency; adjusted operating profit £169.8m, up 7.4% at constant currency; margin 17.5%.
• Fragrances & Flavours +15% at constant currency; Beauty Actives +6%; Beauty Care +4%; Home Care +2%.
• North America demand improved in H2; strong L&R customer momentum with Consumer Care sales to L&Rs up 9% at constant currency.

Life Sciences: Crop recovery and a stronger Q4 in Pharma

• Sales £532.2m, up 7.7% at constant currency; adjusted operating profit £116.5m, up 15.6% at constant currency; margin 21.9%.
• Crop Protection +14% at constant currency on customer inventory rebuild; Seed Enhancement +8%.
• Pharma +4% at constant currency, with Q4 the best quarter; US regulatory uncertainty still a drag.

Industrial Specialties: a useful utilisation outlet, but mixed economics

• Sales £194.5m, down 2.4% at constant currency; adjusted operating profit £9.0m (2024: £15.5m).
• Volumes +7.7% offset by weaker price/mix (-10.1%) from by-product and co-stream sales.

Adjusted vs IFRS: why the gap?

Adjusted results strip out exceptional items and acquisition-related amortisation to show underlying trading. IFRS results include everything. In 2025, IFRS operating profit fell to £110.1m after £185.2m of adjustments, notably:

• Impairments of £107.3m, including £44.6m to place the Lamar, USA lipids facility on standby.
• An onerous contract provision of £15.9m linked to pandemic-preparedness obligations.
• Transformation and restructuring cash costs of £26.3m, and other asset write-downs.

Management calls out non-cash exceptional charges of £60.5m tied to Lamar (impairment plus provision). The strategic read-across: Croda retains ample lipid capacity across four GMP sites, but is right-sizing cost while waiting for large-scale projects to materialise.

Cash, capex and dividend: discipline improving

Free cash flow of £161.6m (post exceptionals) was slightly lower year-on-year, but the second half stepped up thanks to lower capex and better working capital. Capex fell to £108.2m (6% of sales) and is guided to ~6% of sales ahead, with a ~£10m uplift in 2026 depreciation as recent investments come on stream.

Net debt edged down to £523.8m and leverage to 1.3x, with £400.9m of undrawn committed facilities and £172.8m cash at year-end. The dividend is up 1p to 111.0p, though the 76% payout sits above the 40-50% policy while earnings rebuild.

Transformation programme: savings landing, more to come

• £28m gross benefits realised in 2025 (target ~£100m annualised by FY28).
• Working capital programme targeting ~£50m structural reduction by FY28.
• Additional cash costs of ~£55m expected across 2026-28 to unlock the remaining savings.

Early benefits came from supply chain optimisation (~£10m) and organisational simplification (~£15m). The big opportunity now is consistent delivery across Croda’s 11 shared manufacturing sites and portfolio simplification to sharpen mix and service.

Three-year framework to 2028: what success looks like

• Sales growth: 3-6% organic CAGR (2026-28) at constant currency.
• Profitability: adjusted operating margin above 20% by full year 2028 (from 17.4% in 2025).
• Cash: free cash flow-to-sales above 12% by 2028 (2025: 9.5%).
• Returns: ROIC above 10% by 2028 (2025: 8.2%).

The route to get there blends self-help (transformation savings, mix, service) with consistent organic growth in Consumer Care and Life Sciences. Importantly, the period of “heightened investment” is over, so incremental gains should convert better to cash.

2026 outlook and FX sensitivity

• Organic sales growth expected within 3-6% range for the full year.
• Further lift in adjusted operating margin from Consumer Care, Life Sciences and transformation benefits.
• Adjusted operating profit expected to be in line with current market expectations at constant currency.
• Q1 note: tough comparator – Q1 2025 sales were up 9% at constant currency – so Q1 2026 sales expected to be similar year-on-year at constant currency.

FX guide: every 1 cent move in the US Dollar or Euro typically shifts adjusted operating profit by ~£1m. If January 2026 rates held for the rest of the year, reported operating profit would be about £8m lower.

Jargon buster (quickly)

• Constant currency: strips out exchange rate moves to show like-for-like performance.
• Adjusted results: exclude exceptional items and acquisition-related amortisation to show underlying trading.
• EBITDA: earnings before interest, tax, depreciation and amortisation – a proxy for cash operating profit.
• Onerous contract provision: a liability booked when unavoidable costs exceed expected benefits from a contract.

My take: reasons to be encouraged, and what to watch

On the positive side, Croda’s two core engines – Consumer Care and Life Sciences – both grew volumes, margins and profits. The NPS score of +43 (from +32) and a 12% uplift in the value of co-creation projects suggest the commercial machine is humming again. The transformation programme is real – £28m in-year benefits – and the 2028 targets are sensible if execution remains tight.

On the flip side, statutory profit was clobbered by sizeable non-cash charges, and mix was negative as Croda prioritised utilisation – price/mix was -3.0% across the group. Crop Protection benefited from an inventory rebuild that will not repeat in 2026, and Pharma’s lipids breakout remains a waiting game. The dividend payout is high for now, so earnings delivery needs to follow to normalise policy.

What matters next: sustained Beauty momentum beyond North America, evidence of price/mix turning positive as utilisation normalises, Pharma rebalancing traction (especially core ingredients and excipients), and steady, auditable drops through the transformation savings funnel. Cash conversion and working capital reductions are the acid test. Management says Q1 will be flat at constant currency; the more telling read will be H2 margins and mix.

Overall, a credible year of rebuilding with clearer signposts to improved returns. Delivery against the >20% margin and >12% cash conversion targets is the prize.